To further examine whether obesity could affect the anti-tumorigenic potential of everolimus in vivo, we used a transgenic serous ovarian cancer mouse model (KpB, K18-gT121+/–; Brcar1f/f; p53f/f) fed a high fat diet (HFD) or low fat diet (LFD) at 3 weeks of age to induce obesity [9, 24]. This evidence concerns the gene KRT18 and ovarian serous adenocarcinoma.